Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40138-015-0068-8 http://scihub22266oqcxt.onion/10.1007/s40138-015-0068-8 C4518848!4518848!26236569     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Emerg+Hosp+Med+Rep 2015 ; 3 (2): 66-73 Nephropedia Template TP {{tp|p=26236569|t=2015. New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027 |pdf=|usr=}}{{26236569}} gab.com Text New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027 JO: Curr Emerg Hosp Med Rep http://www.kidney.de/pget.php?&tw=1&pmid=26236569 #FOAvip Nitrovasodilators have long been used as first-line treatment for hypertensive acute heart failure (AHF). Although effective for BP control and symptom alleviation, this class of agents has never been shown to improve mortality or prevent hospital readmissions. Consequently, there has been tremendous interest in development of newer vasodilators with more beneficial therapeutic profiles. In this review, we focus on three of the most promising agents currently being studied: serelaxin, ularitide, and TRV027. While regulatory approval has yet to be obtained, should they prove beneficial in on-going trials, we are looking at a new era of drug therapy that could supplant more conventional treatments and broaden the horizon for management of patients with AHF. Twit Text FOAVip New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027 ????Curr Emerg Hosp Med Rep http://www.kidney.de/pget.php?&tw=1&pmid=26236569 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26236569 #FOAvip English Wikipedia <ref>{{Cite pmid|26236569}}</ref> New Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027 #MMPMID26236569 Kumar VA; Viau D; Levy P Curr Emerg Hosp Med Rep 2015[May]; 3 (2): 66-73 PMID26236569show ga Nitrovasodilators have long been used as first-line treatment for hypertensive acute heart failure (AHF). Although effective for BP control and symptom alleviation, this class of agents has never been shown to improve mortality or prevent hospital readmissions. Consequently, there has been tremendous interest in development of newer vasodilators with more beneficial therapeutic profiles. In this review, we focus on three of the most promising agents currently being studied: serelaxin, ularitide, and TRV027. While regulatory approval has yet to be obtained, should they prove beneficial in on-going trials, we are looking at a new era of drug therapy that could supplant more conventional treatments and broaden the horizon for management of patients with AHF. äNew Drugs You Are Going to Read About: Serelaxin, Ularitide, TRV027 (epmc).pdf DeepDyve Pubget Overpricing